News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing The Efficacy And Safety Of LOU064 100 Mg BID Versus Teriflunomide 14 Mg QD In Participants With RMS, Followed By Extended Treatment With Open-Label LOU064

Study Status:

Not Yet Recruiting

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

To demonstrate that LOU064 (100 mg PO bid) is superior to teriflunomide (14 mg PO once daily) in reducing the frequency of confirmed relapses as evaluated by the annualized relapse rate (ARR) in Participants with relapsing MS.

Information: 

Principal Investigator
Roberto A. Cruz Saldana, M.D.
Sponsor
Novartis
Type of Trial
Interventional
© 2022 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram